SFM
REGN icon

Signet Financial Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Signet Financial Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-500
Closed -$1K – 243
2018
Q4 		$1K Sell
500
-3,000
-86% -$1.1M ﹤0.01% 237
2018
Q3 		$110K Buy
3,500
+3,000
+600% +$1.14M 0.02% 302
2018
Q2 		$19K Buy
+500
New +$156K ﹤0.01% 537

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Signet Financial Management's REGN Position: Q1 2026 in Review

Signet Financial Management reduced its Regeneron Pharmaceuticals (REGN) stake by 1.9% in Q1 2026, selling an estimated $59K and leaving 3,895 shares worth $3.01M. The position accounts for 0.34% of the portfolio, ranked #97.

Signet Financial Management first reported a position in REGN in Q2 2018 and has held it in 32 quarters since. The position peaked at $4.24M in Q3 2024. 1,396 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Signet Financial Management held 3,895 shares of Regeneron Pharmaceuticals worth $3.01M as of Q1 2026.
  • Signet Financial Management sold 77 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $59K.
  • Regeneron Pharmaceuticals made up 0.34% of Signet Financial Management's portfolio in Q1 2026, its #97 holding.
  • Signet Financial Management first reported a position in Regeneron Pharmaceuticals in Q2 2018 and has held it in 32 quarters since.
  • Signet Financial Management's Regeneron Pharmaceuticals position peaked at $4.24M in Q3 2024.
  • 1,396 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Signet Financial Management's 13F filing for Q1 2026, filed 5 May 2026.